By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Antibody company Affomix today announced a collaboration with the University of Montreal Pharmacogenomics Centre and the Montreal Heart Institute to develop companion diagnostic biomarkers for cardiovascular disease.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.